REG - Yourgene Health PLC - Collaboration in COVID-19 testing

Yourgene HealthAnnouncement

16/06/2020 07:01

RNS Number : 0294Q
  
Yourgene Health PLC
  
16 June 2020
  
 

 
Yourgene Health plc
("Yourgene" or the "Company")
 
Collaboration in COVID-19 testing
Supporting the effort to get Britain back to work
 
Manchester, UK - 16 June 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a collaboration agreement with international payments company Caxton and immunity passport app Prova, which once launched will support the efforts to get Britain back to work by testing employees for COVID-19.
 
The collaboration with Prova and Yourgene will enable Caxton to offer COVID-19 tests to its extensive network of corporate clients and their employees. The immunity passport app Prova, created by London-based Hooha Innovations, enables employees to download and request a COVID-19 test. Once a test sample has been taken and the sample processed, the results will be automatically delivered securely to the Prova app, allowing the user to share and prove their COVID-19 status without revealing any personal information. 
 
Yourgene's responsibilities will lie in providing the clinical and technical expertise, by providing sample collection kits, training a healthcare professional to take the sample safely and effectively then running the COVID-19 test in its Manchester Citylab facility. The collaboration will use the Company's ClarigeneTM SARS CoV-2 CE-IVD assay when launched and the patient results will be uploaded securely to the Prova app. 
 
As announced on the 26 May 2020, the Company is still on track to release a 'Research Use Only' version of Clarigene SARS-CoV-2 test by the end of June 2020 and achieve a CE marked in vitro diagnostic kit to follow in July 2020.
 
Lyn Rees, CEO of Yourgene, commented: "We are proud to support this effort as the COVID-19 lab partner to this collaboration, working with Caxton and Prova, enabling employees to return to work safely. We look forward to updating the market as the project progresses as we expect to launch in Summer 2020." 
 
Rupert Lee-Browne, CEO of Caxton comments: "Getting Britain back to work is vital for the economy and we are pleased to be able to offer this unique service of test and verify to Caxton's business clients. We chose Yourgene because they match our own values around product quality and reputation and we look forward to helping our customers with this easy solution to creating safe work spaces."
 
Ed Keohane, CEO of Hooha, creators of the Prova app, comments: "We are delighted to be integrating Yourgene Health's high-quality COVID-19 tests to automatically deliver results to Caxton's business customers as part of Back to Work, allowing them to share and prove their COVID-19 health status without revealing any personal information."
 
For further information and to register interest to be a corporate partner and offer this premium high quality COVID-19 testing provision for your employees please visit: https://caxtonfx.com/business
 
For further information on the Prova app please visit: https://provapro.com
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
 
 




Yourgene Health plc
Lyn Rees, Chief Executive Officer


Tel: +44 (0)161 669 8122
investors@yourgene-health.com 




Barry Hextall, Chief Financial Officer


 




Joanne Cross, Director of Marketing


 




 


 




Cairn Financial Advisers LLP (NOMAD)


Tel: +44 (0)20 7213 0880




Liam Murray / James Caithie / Ludovico Lazzaretti


 




 


 




Stifel Nicolaus Europe Limited (Sole Corporate Broker)


Tel: +44 (0)20 7710 7600




Nicholas Moore / Matthew Blawat / Ben Maddison


 




 


 




Walbrook PR Ltd (Media and Investor Relations)


Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com




Paul McManus / Lianne Cawthorne 


Mob: 07980 541 893 / Mob: 07584 391 303



 
 
 



 
 
About Yourgene Health plc
Yourgene is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.  
 
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
 
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene is also extending its genetic testing offering into oncology.
 
Yourgene is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
MSCKKPBKFBKDNAD